Radar · Life Sciences Tech in Massachusetts
Best Life Sciences Tech Companies in Massachusetts, United States
The 287 best Life Sciences Tech companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: XtalPi.
By Rohit KhannaTrends & Stories
287companies tracked
$10.4Bdisclosed funding
4unicorns
140have raised
FLIAR INTELLIGENCE · LIFE SCIENCES TECH × MASSACHUSETTS
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
89%cloud-native stacks
2025funding peak (by rounds)
8unicorns
2018median founding year
749kcombined LinkedIn audience
32%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Life Sciences Tech companies in Massachusetts
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | XtalPi 🦄 AI-based drug research and development company 64Funding top 18%AI top 26%Talent top 28%Patents top 31% All 13 signals ▾Fundingtop 18% AItop 26% Talenttop 28% Patentstop 31% Moattop 31% Innovationtop 34% Producttop 35% Newstop 38% Techtop 39% Growthtop 47% Globaltop 50% Marketbottom 43% Fin. healthbottom 32% Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $785M | 9 mo ago | Public | 27 | — | 14 patents Small-molecule STING agonists and PI3Kβ inhibitors for immuno‑oncology therapeutics | 1 partnership |
| 2 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 18 mo ago | Public | 75 | Gevorg Grigoryan Co-Founder & CTO | 36 patents Patents concentrated in chemistry & materials | — |
| 3 | Nimbus Therapeutics Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 33 mo ago | Series F | 81 81 → 99 (+22%) · sector median +36% | Jeb Keiper CEO | — | — |
| 4 | Relay Therapeutics Developer of drug discovery platform and study protein motion | $520M | 29 mo ago | Public | 245 245 → 218 (-11%) · sector median +36% | David Shaw Co-Founder | 234 patents Small-molecule FGFR and PI3Kα kinase inhibitors for oncology applications | — |
| 5 | Reify Health 🦄 Mobile health platform for doctors to manage clinical trials | $478M | 49 mo ago | Series D | 71 | Michael Lin Executive Chairman & Co-Founder | — | — |
| 6 | Valo Health AI-powered platform for drug discovery and development | $450M | 63 mo ago | Series B | 117 117 → 214 (+83%) · sector median +36% | Brian Alexander Chief Executive Officer | 150 patents Organ-on-chip 3D tissue platforms and ubiquitin‑targeted small‑molecule therapeutics | 1 award |
| 7 | In Silico AI-enabled bioinformatics platform for drug discovery and biomarker development 82Funding top 15%Product top 19%AI top 20%News top 26% All 12 signals ▾Fundingtop 15% Producttop 19% AItop 20% Newstop 26% Partnerstop 26% Talenttop 28% Moattop 31% Innovationtop 35% Growthtop 35% Markettop 43% Techtop 46% Globalbottom 39% Funding: Raised $400M across 11 rounds · 11 rounds over 12 yrs (0.9/yr) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 82/100 | $400M | 17 mo ago | Public | 300 | Alex Zhavoronkov Co-Founder & Co-CEO | — | — |
| 8 | SmartLabs Developer of smart labs and lab spaces | $334M | 29 mo ago | Series C | 172 | Amrit Chaudhuri Co-Founder & CEO | 76 patents IoT-based communication and control systems for smart building automation and modular devices | 2 expansions |
| 9 | Concert AI 🦄 Provider of AI and real-world data solutions for life sciences | $300M | 50 mo ago | Series C | 1,000 | — | 139 patents Patents concentrated in electrical & electronics | — |
| 10 | Cellarity AI-powered drug design and development platform | $294M | 44 mo ago | Series C | 117 117 → 72 (-38%) · sector median +36% | — | 26 patents AI-driven drug discovery and cellular diagnostic platforms using heterocyclic modulators | — |
| 11 | PathAI Provider of digital pathology image management system for clinical labs | $255M | 61 mo ago | Series C | 573 | Andrew Beck Co-Founder & CEO | 45 patents AI-driven digital pathology analysis and tissue characterization using advanced machine learning models | 1 launch |
| 12 | METiS Therapeutics Provider of an AI-assisted platform for drug discovery and development | $252M | 50 mo ago | Series B | 33 | Wenshou Wang Co-Founder | — | 1 partnership |
| 13 | Seismic AI-assisted platform for drug discovery and development | $247M | 31 mo ago | Series B | 15 | Timothy Springer Co-Founder | 47 patents Wearable assistive exosuits for posture correction, biomechanical feedback, and related data processing | — |
| 14 | Apprentice AI-based manufacturing processing and management tool for pharmaceutical industry | $247M | 39 mo ago | Series C | 152 | Angelo Stracquatanio III Co-Founder & CEO | 53 patents Remote digital workflow automation and video guidance for legacy manufacturing equipment | — |
| 15 | HotSpot Therapeutics Developer of a platform for protein function analysis | $210M | 54 mo ago | Series C | 37 37 → 59 (+59%) · sector median +36% | Jonathan Montagu President & Chief Executive Officer | — | — |
| 16 | Asimov Provider of integrated suite for advanced genetic design and manufacturing | $209M | 41 mo ago | Series B | 64 64 → 119 (+86%) · sector median +36% | Chris Voigt Co-Founder | 70 patents Efficient manufacturing of recombinant viral vectors for gene therapy applications | 1 launch · 1 partnership |
| 17 | Evolved By Nature Developer of bioactive peptides derived from silk protein for skincare | $190M | 47 mo ago | Series C | 101 | Gregory Altman Co-Founder & CEO | 230 patents Silk-based biopolymers for performance textiles, cosmetics, and hyaluronic‑acid medical fillers | 1 award |
| 18 | Harbinger Health AI-based cancer detection tool for providers 55Funding top 18%News top 36%Moat top 42%AI top 45% All 8 signals ▾Fundingtop 18% Newstop 36% Moattop 42% AItop 45% Talenttop 49% Techbottom 48% Marketbottom 43% Globalbottom 38% Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership rank vs industry peers · Fliar Intelligence Index 55/100 | $140M | 2 mo ago | Series B | 60 | Stephen Hahn CEO | — | 2 launchs |
| 19 | Diagonal Therapeutics Developer of antibody therapeutics for the treatment of rare diseases 40Funding top 19%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 19% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 38% Funding: Raised $128M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $128M | 5 mo ago | Series B | — | Alexey Lugovskoy CEO | — | — |
| 20 | Zageno Marketplace and life science research community for biotech research kits | $121M | 36 mo ago | Series C | 51 51 → 127 (+149%) · sector median +36% | Florian Wegener Co-Founder & CEO | — | 1 launch |
| 21 | Entact Bio Developer of drugs to enhance the functions of beneficial proteins | $121M | 28 mo ago | Series A | 32 | Sara Buhrlage Founder | — | — |
| 22 | Stipple Bio Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target… 21Funding top 20%Talent top 38%Global bottom 48%Tech bottom 25% All 5 signals ▾Fundingtop 20% Talenttop 38% Globalbottom 48% Techbottom 25% Marketbottom 19% Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $109M | 2 mo ago | Series A | 2 | Aaron Ring Co-Founder | — | 1 partnership |
| 23 | Atavistik Developer of allosteric therapeutics for precision oncology and rare diseases 50Funding top 19%Talent top 28%Moat top 31%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 28% Moattop 31% Marketbottom 42% Globalbottom 36% Newsbottom 33% Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 3 mo ago | Series B | 33 | Ralph DeBerardinis Co-Founder | — | — |
| 24 | TetraScience Provider of a cloud-based data platform for life science industry 40Funding top 21%Growth top 26%Moat top 35%Tech top 50% All 9 signals ▾Fundingtop 21% Growthtop 26% Moattop 35% Techtop 50% Newsbottom 47% Globalbottom 39% Marketbottom 38% Patentsbottom 25% Innovationbottom 22% Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $99M | 4 mo ago | Series B | 30 | — | 4 patents Real-time monitoring and feedback control systems for industrial tools and equipment | 1 job opening |
| 25 | GRO Biosciences Developer of re-coding synthetic biology tools | $91M | 23 mo ago | Series B | 22 | Daniel Mandell CEO | — | — |
| 26 | AcuityMD Platform offering CRM software to the medical industry 53Funding top 18%News top 25%Talent top 28%Growth top 35% All 10 signals ▾Fundingtop 18% Newstop 25% Talenttop 28% Growthtop 35% Producttop 36% Moattop 39% Techtop 48% Marketbottom 42% Innovationbottom 37% Globalbottom 34% Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | Series C | 48 | Michael Monovoukas Co-Founder & CEO | — | — |
| 27 | DeepCure AI-driven drug discovery platform for inflammation & immunology space | $72M | 26 mo ago | Series A | 22 22 → 27 (+23%) · sector median +36% | Kfir Schreiber Co-Founder & CEO | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 28 | Transition Bio Developer of a technology platform for the analysis of biomolecular condensate | $69M | 20 mo ago | Series B | 9 | David Weitz Co-Founder | — | — |
| 29 | Ampersand Developer of programmable medicines to treat multiple diseases 42AI top 15%Funding top 24%Talent top 38%Moat top 40% All 10 signals ▾AItop 15% Fundingtop 24% Talenttop 38% Moattop 40% Growthtop 43% Patentsbottom 45% Techbottom 43% Globalbottom 38% Innovationbottom 30% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) Funding: Raised $65.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $65M | 14 mo ago | Series B | 22 | Raffi Afeyan Co-Founder & Chief Innovation Officer | 5 patents Audio signal analysis and filtering, plus multidimensional GUI for database interaction | 1 partnership |
| 30 | DeepCure Developer of novel small molecule therapies for immune diseases | $65M | 26 mo ago | Series A | — | Thrasyvoulos Karydis Co-Founder & CTO | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 31 | Metaphore Provider of machine language and computational platform for drug discovery 42Funding top 23%Talent top 28%Moat top 42%AI top 45% All 7 signals ▾Fundingtop 23% Talenttop 28% Moattop 42% AItop 45% Globalbottom 36% Techbottom 35% Marketbottom 31% Funding: Raised $50.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $50M | 2 mo ago | Series C | 30 | Noubar Afeyan Co-Founder | — | — |
| 32 | Magnet Biomedicine Developer of a research platform for molecular glue medicines | $50M | 33 mo ago | Series A | 20 | Stuart Schreiber Co-Founder | — | — |
| 33 | Oncimmune Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | $49M | 19 mo ago | Acquired | 62 62 → 35 (-44%) · sector median +36% | Jamie Heywood Managing Director | 4 patents Immunoassay development and calibration technologies for diagnostic testing | — |
| 34 | Centaur Labs Provider of medical data labeling solutions for AI development | $31M | 20 mo ago | Series B | — | Zach Rausnitz Co-Founder & CTO | 68 patents Microprocessor architecture and design, focusing on branch prediction, multi‑core, and clock generation | 2 job openings |
| 35 | Pi Health Provider of an AI-native platform for managing clinical trials end-to-end 62Patents top 20%Moat top 21%Growth top 28%Innovation top 31% All 11 signals ▾Patentstop 20% Moattop 21% Growthtop 28% Innovationtop 31% Fundingtop 31% Talenttop 38% AItop 45% Techbottom 47% Globalbottom 45% Marketbottom 29% Newsbottom 18% Patents: 9,865 patents matched (strict assignee match) · 2246 filings since 2022 vs 3287 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 9,865 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $31M | 4 mo ago | Series A | — | Bobby Reddy Md Co-Founder and COO | 9,865 patents Cell-based immunotherapies, engineered NK/CAR cells, and PET imaging agents for oncology | 1 job opening |
| 36 | Labviva Digital marketplace for life science products | $31M | 17 mo ago | Series B | 8 | Nicholas Rioux Co-Founder & CTO | — | 1 launch · 4 partnerships |
| 37 | 1910 Genetics Developer of small molecule therapeutics to treat pain and aging-related diseases | $30M | 19 mo ago | Series A | 18 | Jen Nwankwo Founder & CEO | — | — |
| 38 | Sware Provider of a platform for validation automation for regulated systems | $26M | 26 mo ago | Series B | 107 | Bryan Ennis President & Co-Founder | — | — |
| 39 | Xellar Developer of an AI-based computational platform for drug discovery | $24M | 23 mo ago | Series A | 12 | Xin Xie Co-Founder | 6 patents Patents concentrated in computing, sensing & instrumentation | — |
| 40 | Ketryx Provider of AI-native compliance software for regulated medical applications development 45Funding top 30%Tech top 40%AI top 45%Growth top 48% All 9 signals ▾Fundingtop 30% Techtop 40% AItop 45% Growthtop 48% Talentbottom 49% Moatbottom 48% Marketbottom 32% Newsbottom 31% Globalbottom 29% Funding: Raised $18.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Tech: 36 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 45/100 | $18M | 11 mo ago | Series B | 19 | Erez Kaminski CEO | — | — |
| 41 | Consensus Provider of an AI-enabled search tool for research purposes | $18M | 22 mo ago | Series B | 6 | Christian Salem Co-Founder | — | 1 launch |
| 42 | Clinical Research IO Provider of a clinical trial management software for researcher | $17M | 24 mo ago | Series B | 16 | — | — | 1 partnership |
| 43 | Matterworks AI and analytical platform to accelerate therapeutic research | $16M | 12 mo ago | Series A | 14 | Jack Geremia Chief Executive Officer | 12 patents Predictive mass‑spectrometry analytics and quantitative analyte measurement solutions. | 1 launch |
| 44 | Genialis Developer of end-to-end bioinformatics software solutions 53Funding top 33%Growth top 35%Moat top 37%Patents top 38% All 10 signals ▾Fundingtop 33% Growthtop 35% Moattop 37% Patentstop 38% Innovationtop 39% Talenttop 41% Producttop 46% Techtop 50% Globalbottom 44% Marketbottom 35% Funding: Raised $15.3M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $15M | 6 mo ago | Series A | 35 | Rafael Rosengarten Chief Executive Officer | 17 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 45 | PhaseV DIgital platform for clinical trial design and closed-loop execution | $15M | 13 mo ago | Series A | 15 | — | — | — |
| 46 | Phylo Developer of collaborative agents designed for biologists to accelerate discoveries 42Funding top 32%Talent top 38%Tech top 40%Market bottom 37% All 5 signals ▾Fundingtop 32% Talenttop 38% Techtop 40% Marketbottom 37% Globalbottom 33% Funding: Raised $13.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $14M | 4 mo ago | Seed | — | Yuanhao Qu Co-Founder & President | — | 1 launch · 3 partnerships |
| 47 | Somite AI-driven platform to produce human tissue for cell-based therapies | $10M | 13 mo ago | Series A | — | Jay Shendure Co-Founder | — | — |
| 48 | NeoSoma Provider of an AI-based image analysis and decision-making platform for neurooncologist 40AI top 28%Funding top 40%Patents top 40%Moat top 42% All 8 signals ▾AItop 28% Fundingtop 40% Patentstop 40% Moattop 42% Innovationtop 48% Talentbottom 49% Globalbottom 35% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) · Product described with: ai-based Funding: Raised $6.3M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $6M | 3 mo ago | Series B | 13 | Ken Kolodziej Co-Founder & CEO | 7 patents AI-driven MRI segmentation and volumetric analysis of high-grade brain gliomas | — |
| 49 | Basil Systems Provider of AI-powered regulatory, clinical and safety intelligence platform for life sciences | $6M | 13 mo ago | Series A | 11 | Anthony Cirurgiao CEO | — | — |
| 50 | QSimulate Laboratory focused on developing of quantitative simulation tools to help in quantum molecular 32Growth top 35%Talent top 38%Funding top 41%Moat top 48% All 7 signals ▾Growthtop 35% Talenttop 38% Fundingtop 41% Moattop 48% Techbottom 36% Globalbottom 36% Marketbottom 24% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $4M | 6 mo ago | Seed | 14 14 → 21 (+50%) · sector median +36% | Toru Shiozaki Co-Founder & CEO | — | 1 job opening |
Top 12 Life Sciences Tech companies in Massachusetts
#1
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees$140Mraised▾
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees
AI-based cancer detection tool for providers. The company has developed a blood test detection tool that enables professionals to analyze and detect early cancers.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 18%News
top 36%Moat
top 42%AI
top 45%Talent
top 49%Tech
bottom 48%Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Apr 2026)
News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Apr 2026Series B$100M
- Sep 2023Series B$140M
- 2021Series A$50M
Founders & team
Investors
Flagship Pioneering, Pictet Group, Partners Investment, Venture Catalysts, M&G, Camillus LifeSciences
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsGoogle AnalyticsGoogle Font Api
#2
XtalPi 🦄Public · Cambridge, Massachusetts · founded 2014 · 27 employees$784.8Mraised▾
XtalPi 🦄
Public · Cambridge, Massachusetts · founded 2014 · 27 employees
XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The company's algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 18%AI
top 26%Talent
top 28%Patents
top 31%Moat
top 31%Innovation
top 34%Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Post IPO (Sep 2025)
AI: Classified as an AI company · Product described with: ai-based, machine learning
Talent: Analyst team rating 4/5
Audience (LinkedIn): 18k LinkedIn followers — 2.3% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. OpenEye, Cadence Molecular Sciences) announced in 12 mo
Funding rounds
- Sep 2025Post IPO$268M
- Feb 2025Post IPO$268.4M
- Aug 2021Series D$400M
- Sep 2020Series C$318.8M
Investors
Tencent, Frees Fund, Zhen Fund, Renren, SoftBank Vision Fund, People's Insurance Company of China
Tech stack
Animate.CssBootstrapCdnjsCloudflareCloudflare Bot ManagementCore-Js
#3
Series C · Boston, Massachusetts · founded 2018 · 48 employees$83Mraised▾
Series C · Boston, Massachusetts · founded 2018 · 48 employees
Platform offering CRM software to the medical industry. The platform enables members to personalize customer engagement, identify and quantify opportunities, forecast sales accurately, understand the value of the sales pipeline, empower the sales team, track new launches, understand product adoption and market penetration.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 18%News
top 25%Talent
top 28%Growth
top 35%Product
top 36%Moat
top 39%Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Apr 2026)
News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Apr 2026Series C$80M
- Jun 2024Series B$45M
- May 2022Series A$31M
- May 2021Series A$7M
Founders & team
Investors
Iconiq Capital, Atreides Management, StepStone Group, Redpoint Ventures, Benchmark, Artisanal Ventures
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsFacebook Pixel
#4
Series A · Cambridge, Massachusetts · founded 2021 · 2 employees$109.5Mraised▾
Series A · Cambridge, Massachusetts · founded 2021 · 2 employees
Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target discovery. The platform technology enables single-cell profiling and target identification for ddrug discovery and development of cancer immunotherapy and others.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Global
bottom 48%Tech
bottom 25%Market
bottom 19%Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 1 country beyond United States
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Lonza) announced in 12 mo
Funding rounds
- Mar 2026Series A$100M
- Dec 2024Series A$9.5M
Founders & team
Investors
RA Capital Management, Andreessen Horowitz, Nextech Invest, Emerson Collective, Google Ventures, GordonMD Global Investments
Tech stack
AstraCore-JsElementorGoogle Font ApiGoogle Hosted LibrariesJquery
#5
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees$100Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees
Developer of allosteric therapeutics for precision oncology and rare diseases. The company integrated with proprietary drug discovery platform that enables to unlock novel allosteric binding pockets and rapidly advance structural insights into small molecule therapeutics designt to unlock cryptic allosteric sites across a broad range of target classes.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 19%Talent
top 28%Moat
top 31%Market
bottom 42%Global
bottom 36%News
bottom 33%Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Mar 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Mar 2026Series B$40M
- Dec 2025Series B$120M
- Dec 2023Series A$40M
- Aug 2021Series A$60M
Founders & team
Investors
The Column Group, Lux Capital, Nextech Invest, Regeneron Ventures, RA Capital Management
#6
Series B · Boston, Massachusetts · founded 2014 · 30 employees$99.2Mraised▾
Series B · Boston, Massachusetts · founded 2014 · 30 employees
Provider of a cloud-based data platform for life science industry. It provides a platform that automatically gathers scientific data from lab equipment, gets data ready for analysis and display, and re-engineers raw or primary data into harmonised data.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 21%Growth
top 26%Moat
top 35%Tech
top 50%News
bottom 47%Global
bottom 39%Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series B (Feb 2026)
Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 8/10 · IP moat: 4 patents · Soonicorn
Audience (LinkedIn): 57k LinkedIn followers — 7.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Product Manager
Funding rounds
- Feb 2026Series B$15M
- Apr 2021Series B$80M
- 2020Series A$11M
- Oct 2019Series A$8M
Investors
Underscore VC, Impetus VC, Alkeon Capital Management, Insight Partners, Y Combinator, Founder Collective
Tech stack
6SenseAmazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot Management
#7
Series B · Cambridge, Massachusetts · founded 2022$128Mraised▾
Series B · Cambridge, Massachusetts · founded 2022
Developer of antibody therapeutics for the treatment of rare diseases. The company's DIAGONAL platform combines proprietary computational and experimental techniques to develop agonist antibody therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 19%Moat
top 42%Talent
bottom 49%Market
bottom 40%Global
bottom 38%Funding: Raised $128M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series B (Jan 2026)
Moat: Editorial + unicorn rating 5/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Jan 2026Series B$125M
- Apr 2024Series A$128M
Founders & team
Investors
VF Partners, Atlas Venture, CHECKPOINT, Frazier Life Sciences, Lightspeed Venture Partners, RA Capital Management
#8
Series C · Cambridge, Massachusetts · founded 2021 · 30 employees$50Mraised▾
Series C · Cambridge, Massachusetts · founded 2021 · 30 employees
Provider of machine language and computational platform for drug discovery. The company uses biomimicry and machine learning to unleash the transformational medicinal potential of functional molecular mimics. The MIMiC platform, developed by the company is a computationally driven bioplatform for developing novel therapies in which function, specificity, and selectivity may be optimized.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 23%Talent
top 28%Moat
top 42%AI
top 45%Global
bottom 36%Tech
bottom 35%Funding: Raised $50.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) · Last round Series C (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Apr 2026Series C—
- May 2023Series C$50M
Founders & team
Investors
Flagship Pioneering, TOHO HOLDINGS
Tech stack
CloudflareHstsHttp/3JqueryMicrosoft 365Webflow
#9
Series A · Boston, Massachusetts · founded 2021$30.9Mraised▾
Series A · Boston, Massachusetts · founded 2021
Provider of an AI-native platform for managing clinical trials end-to-end. The platform unifies systems to power faster and higher-quality trials. It operates on a single shared record, eliminating manual reconciliation. Amendments propagate automatically across all workflows, preventing version mismatches. The system provides a unified audit trail across the entire trial process. It integrates AI into operational workflows to improve speed and quality.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 20%Moat
top 21%Growth
top 28%Innovation
top 31%Funding
top 31%Talent
top 38%Patents: 9,865 patents matched (strict assignee match) · 2246 filings since 2022 vs 3287 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 7/10 · IP moat: 9,865 patents
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: East Coast Clinical Trial Manager
Funding rounds
- Jan 2026Series A$8.6M
Founders & team
Investors
AlleyCorp, Obvious Ventures
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesCore-JsKlaroMicrosoft 365
#10
Public · Somerville, Massachusetts · founded 2018 · 75 employees$643Mraised▾
Public · Somerville, Massachusetts · founded 2018 · 75 employees
Developer of a platform for generating novel protein-based therapeutic modalities. The platform aims to expand technical possibilities to change how medicines are made. It studies proteins to learn rules by which nature encodes function. The company generates medicines across therapeutic modalities with speed and success.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
AI
top 18%Funding
top 23%News
top 24%Innovation
top 25%Growth
top 25%Patents
top 25%AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC)
Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series C (Dec 2024)
News: 6 BI events in 12 mo (of 13 tracked, 3 types) · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO
Audience (LinkedIn): 58k LinkedIn followers — 7.7% of this cohort's audience
Funding rounds
- Dec 2024Series C—
- Sep 2023Series C$273M
- Nov 2021Series B$370M
- Sep 2020Series A$50M
Founders & team
Investors
Amgen, Mirae Asset Capital, Pictet Group, ADIA, Fidelity Investments, T. Rowe Price
Tech stack
Amazon Web ServicesApple Icloud MailCookiebotCraft CmsGoogle AnalyticsGsap
#11
Public · Cambridge, Massachusetts · founded 2014 · 300 employees$399.8Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 300 employees
AI-enabled bioinformatics platform for drug discovery and biomarker development. The company provides solutions and services such as custom drug discovery engines, biomarker discovery, and aging research tools to academia, pharmaceutical, and cosmetics companies. Also, it has developed a product PHARMA.AI which includes modules for drug discovery such as PandaOmics, Chemistry42, and InClinico.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 15%Product
top 19%AI
top 20%News
top 26%Partners
top 26%Talent
top 28%Funding: Raised $400M across 11 rounds · 11 rounds over 12 yrs (0.9/yr) · Last round Series E (Jan 2025)
Product: 3 distinct product lines · Company stage: Public
AI: Classified as an AI company
Audience (LinkedIn): 88k LinkedIn followers — 11.7% of this cohort's audience
Funding rounds
- Jan 2025Series E$110M
- Aug 2022Series D$35M
- Jun 2022Series D$60M
- Jun 2021Series C$255M
Founders & team
Investors
Prosperity7 Ventures, Qiming Venture Partners, BHR, Warburg Pincus, Bold Capital Partners, Pavilion Capital Partners
Tech stack
Amazon SesAmazon Web ServicesDdos-GuardEmotionGoogle AnalyticsGoogle Font Api
#12
Series B · Boston, Massachusetts · founded 2019 · 13 employees$6.3Mraised▾
Series B · Boston, Massachusetts · founded 2019 · 13 employees
Provider of an AI-based image analysis and decision-making platform for neurooncologist. The company has developed an AI-enabled neurooncology platform that assists doctors in clinical management. The company has developed platforms like RANO (Response Assessment Neuro-oncology Criteria) that are made for clinical decision making. It provides 2D image analysis tools for brain tumors. There is an automated version called Neosoma-Glioma Automates RANO. The platform has a medical imaging technology for precise analysis of patients' reports and information. Its products are based and developed on MRI sequences for analysis and modeling.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
AI
top 28%Funding
top 40%Patents
top 40%Moat
top 42%Innovation
top 48%Talent
bottom 49%AI: Holds AI/ML patents (G06N-family CPC) · Product described with: ai-based
Funding: Raised $6.3M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series B (Mar 2026)
Patents: 7 patents matched (strict assignee match) · 7 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 914 LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Inselspital (Insel) and Neosoma GmbH) announced in 12 mo
Funding rounds
- Mar 2026Series B$3.5M
- Dec 2024Series A$345K
- Jul 2024Series A$5.1M
- Aug 2023Seed$1.2M
Founders & team
Funding & investor landscape
$10.4Btotal disclosed funding
136companies funded
404disclosed rounds
5rounds last 90 days
Most active investors
Y Combinator6 rounds
Notable founders
Stephen Hahn
CEO · Harbinger Health
Michael Monovoukas
Co-Founder & CEO · AcuityMD
Robert Coe
Co-Founder & CTO · AcuityMD
Aaron Ring
Co-Founder · Stipple Bio
Aashish Manglik
Co-Founder · Stipple Bio
Ralph DeBerardinis
Co-Founder · Atavistik
Jared Rutter
Co-Founder · Atavistik
Alexey Lugovskoy
CEO · Diagonal Therapeutics
Noubar Afeyan
Co-Founder · Metaphore
Lovisa Afzelius
Co-Founder & CEO · Metaphore
Bobby Reddy Md
Co-Founder and COO · Pi Health
Geoffrey Kim
Chief Executive Officer; Co-Founder · Pi Health
Prism market signals · United States · country-scoped Prism corpus, 2,593,976 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Biotechnology in Massachusetts is moving
A read on the academic research around Biotechnology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 169 papers.
MGH, MIT, and UMass Chan lead Massachusetts biotech research, focusing optimistically on RNA interference, CRISPR, and biosensing, with breakthroughs dominating over concerns.
169 papers · stance +0.51 · 51% breakthrough · 18% concern
top institutions
- Massachusetts General Hospital62
- Massachusetts Institute of Technology58
- University of Massachusetts Chan Medical School20
- University of Massachusetts Amherst18
- University of Massachusetts Boston7
leading researchers
David Julian McClements · Michael R. Hamblin · Ying‐Ying Huang · Aaron Chen · Allan S. Myerson · Alper James Alcaraz
prism intelligence · tone & topics
92% positive · 3% critical tone
PharmaceuticalsMedical ResearchHealthGeneticsClinical TrialsBiology
▲
Breakthroughs73 · 43%
▼ 50%→35% share
▼0.7× share momentum388 median citations40% since 2021mostly empirical
Messenger RNA breakthrough research is rising — papers tripled from 1 to 3 despite Breakthroughs segment share falling 50%→35%.
rising sub-themes (early→recent)
- Messenger RNA1→3
- Transcription (linguistics)3→4
Landmark Comprehensive molecular profiling of lung adenocarcinoma · 5,754 cites
◆
Advancements44 · 26%
▲ 26%→28% share
▲1.1× share momentum1 median citations52% since 2021mostly empirical
In vivo research dominates Advancements at 10 papers as segment share grows 26%→28%, signaling intensifying focus.
rising sub-themes (early→recent)
- In vivo10
- Biodistribution3
- Sustainability2
- Population2
- Cell2
Landmark Fear Extinction as a Model for Translational Neuroscience: Ten Years of Progress · 1,441 cites
▼
Concerns25 · 15%
▲ 11%→16% share
▲1.5× share momentum2 median citations56% since 2021mostly reviews
Concerns segment is intensifying — field-share climbed 11%→16%, with Food industry and Biochemical engineering each reaching 3 papers.
rising sub-themes (early→recent)
- Food industry3
- Biochemical engineering3
- Glioma2
- Food science2
- Synthetic biology2
Landmark Genomic responses in mouse models poorly mimic human inflammatory diseases · 2,962 cites
Common questions
How many Life Sciences Tech companies are there in Massachusetts, United States?
Radar tracks 287 indexable Life Sciences Tech companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences Tech companies in Massachusetts, United States?
The Life Sciences Tech companies in Massachusetts, United States on this list have raised a combined $10.4B in disclosed equity funding across 136 funded companies.
Which is the highest-funded Life Sciences Tech company in Massachusetts, United States?
XtalPi is the highest-funded Life Sciences Tech company in Massachusetts, United States, with $784.8M in disclosed equity funding.
How many Life Sciences Tech companies in Massachusetts, United States are funded?
136 of the 287 Life Sciences Tech companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Life Sciences Tech unicorns are there in Massachusetts, United States?
4 Life Sciences Tech companies in Massachusetts, United States on this list are valued at $1B or more.
Who are the top investors in Massachusetts, United States Life Sciences Tech companies?
The most active investors in Massachusetts, United States Life Sciences Tech companies on this list include HHS, Flagship Pioneering, MIT Startup Exchange, MassChallenge, RA Capital Management.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.